Daclatasvir is an antiviral compound used as an active pharmaceutical ingredient in combination therapies for hepatitis C virus infection. It functions as a direct-acting antiviral agent targeting viral replication.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Daclatasvir?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Daclatasvir dihydrochloride
pharmaceutical raw material
Ravidasvir
pharmaceutical raw material
Vistusertib
pharmaceutical raw material
Levofloxacin
pharmaceutical raw material
Pyridostigmine bromide
pharmaceutical raw material
Hyoscyamine
pharmaceutical raw material
Bis(2-methyl-2-propanyl) (2S,2'S)-2,2'-[4,4'-biphenyldiylbis(1H-imidazole-4,2-diyl)]di(1-pyrrolidinecarboxylate)
pharmaceutical intermediate
2-((2S)-Pyrrolidin-2-yl)-5-(4-(4-(2-((2S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl)phenyl)-1himidazole tetrahydrochloride
pharmaceutical intermediate
The international HS code for Daclatasvir (CAS 1009119-64-5) is 2933.29.
2933.29
2933 29 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
FKRSSPOQAMALKA-CUPIEXAXSA-N
CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
Sourcing Daclatasvir?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.